| Business Summary | | EntreMed,
Inc.
is
a
clinical-stage
biopharmaceutical
company
that
develops
and
tests
product
candidates
that
address
the
role
of
blood
and
blood
vessels
in
health
and
disease.
Angiogenesis
is
the
biological
process
by
which
new
blood
vessels
are
formed.
As
"The
Angiogenesis
Company,"
EntreMed
is
primarily
focused
on
developing
antiangiogenic
drugs
designed
to
inhibit
the
abnormal
new
blood
vessel
growth
associated
with
cancer,
as
well
as
a
broad
range
of
diseases
including
certain
types
of
blindness
and
atherosclerosis.
EntreMed's
current
portfolio
of
antiangiogenic
product
candidates
includes
Endostatin,
Panzem
and
Angiostatin,
the
patent
rights
for
all
of
which
are
exclusively
licensed
to
the
Company
by
Children's
Hospital,
Boston. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | ENMD
researches
and
develops
biopharmaceutical
products
that
address
the
role
of
blood
and
blood
vessels
in
the
prevention
of
a
broad
range
of
diseases.
For
the
six
months
ended
6/30/01,
revenues
increased
3%
to
$1.6
million.
Net
loss
increased
7%
to
$25.5
million.
Revenues
reflect
an
increase
in
royalty
income
from
Celgene
Corporation
on
the
sale
of
THALOMID(R).
Higher
loss
reflects
an
increase
in
personnel
expenses
and
a
rise
in
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Holaday, Ph.D., 55 Chairman,
CEO | $401K | $2.1M | Edward Gubish, Ph.D., 52 Pres,
COO | 259K | -- | Wendell Starke, 59 Vice
Chairman | -- | -- | Thomas Russo, 51 CFO | -- | -- | Joanna Horobin, M.D., 46 Exec.
VP of Commercial Devel. | 259K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|